medigraphic.com
ISSN 0210-5187 (Electronic)

2015, Number S1

<< Back Next >>

Med Cutan Iber Lat Am 2015; 43 (S1)

Xanthomas associated with the use of biological therapy. Case report

Mora Ó, Argote A, Barrera D, Muñoz LM, Malpica A, Castro MCA

Language: Spanish
References: 11
Page: 65-68
PDF size: 293.76 Kb.


ABSTRACT

Xanthomas are yellow erythematous papules, uncommon and benign. The association with the use of biological therapy is not clear; however, is important to know the dermatological manifestations. We present the case of a 50 year old patient with rheumatoid arthritis treated with immunomodulators, who presented skin lesions, associated with pruritus, valued for dermatology who diagnose eruptive xanthomas secondary to mixed hyperlipidemia in association with use of biologic therapy.


REFERENCES

  1. Patterson J. Practical skin pathology: a diagnostic approach [Internet]. Philadelphia, PA: Elsevier; 2010. pp. 19103-2899 [cited 20-09-2014]. Available from: https://catalogo.fucsalud.edu.co:2124/#!/browse/book/3-s2.0-C20090359711. Cited nov-2014

  2. Burns T, Breathnach S, Cox N, Griffiths C. Rook’s textbook of dermatology. 4 Volume Set. 8th edition. Oxford: John Wiley & Sons; 2010.

  3. Descalzo M. Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas (BIOBADASER): informe de la situación, 26 de enero de 2006. Reumatol Clin. 2007; 3 (1): 4-20.

  4. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 Suppl 5: v38-47.

  5. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008; 58 (10): 2968-2980.

  6. Ladizinski B, Lee KC. Eruptive xanthomas in a patient with severe hypertriglyceridemia and type 2 diabetes. CMAJ. 2013; 185 (18): 1600.

  7. Marks J. Lookingbill and Marks’ principles of dermatology. Hershey, PA, USA: 2013 [cited 20-09-2014]. Available from: https://catalogo.fucsalud.edu.co: 2124/#!/content/book/3-s2.0-B978145572875600025X.

  8. Bolognia J, Schaffer J. Dermatology. 3rd edition. New Haven, CT, USA: 2012 [cited 20-09-14]. Available from: https://catalogo.fucsalud.edu.co:2124/#!/content/book/3-s2.0-B9780723435716001652.

  9. Saavedra P, González L. Interleucina-6: ¿amiga o enemiga? Bases para comprender su utilidad como objetivo terapéutico. Antoquia médica. Iatreia. 2011; 24 (2): 157-166.

  10. Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 2011; 31 (4): 451-456.

  11. Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JHM et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013; 229 (1): 174-181.




2020     |     www.medigraphic.com